An Evidence-Based Approach to Myeloma Bone Disease

Nicholas Bingham, Antonia Reale, Andrew Spencer

Research output: Contribution to journalReview ArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Multiple myeloma is an incurable clonal plasma cell malignancy characterised by osteolytic bone lesions and the presence of a monoclonal immunoglobulin. The bone disease caused by myeloma is a major cause of morbidity with the related complications of pathological fractures, hypercalcaemia and bone pain affecting both quality of life and patient survival. The osteolytic lesions arise due to an imbalance of osteoclast and osteoblast function, arising from complex interactions between myeloma cells, bone marrow stromal cells and the bone marrow microenvironment. These advances in understanding of the pathophysiology have directly led to improvements in patient management and outcomes. Recent advances in myeloma bone disease are reviewed, including the role of novel and emerging therapies, and evidence-based management strategies for myeloma bone disease are discussed.

Original languageEnglish
Pages (from-to)109-118
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Volume12
Issue number2
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Multiple myeloma
  • Myeloma bone disease
  • RANK/RANKL pathway

Cite this